Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Duloxetine hydrochloride sustained release medicine

A technology for duloxetine hydrochloride and sustained-release drugs, which is applied in the field of duloxetine hydrochloride sustained-release drugs, can solve problems such as adverse reactions and limit clinical drug doses, achieve strong drug efficacy, enhance drug compliance and clinical treatment Effect, the effect that the manufacturing process is easy to control

Active Publication Date: 2008-04-23
CHONGQING SHENGHUAXI PHARMA CO LTD
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although the adverse reactions of this drug are relatively small among comparable drugs of the same kind, there are still obvious adverse reactions during the medication process, especially nausea in the gastrointestinal tract is the most obvious, and the incidence rate can be as high as 23% to 28%. And it is also the main reason for patients to discontinue treatment, limiting the clinical dosage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Duloxetine hydrochloride sustained release medicine
  • Duloxetine hydrochloride sustained release medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Get 15 parts of hydroxypropylmethylcellulose K15M (weight, the same below) 9.5 parts of glycine, 9.5 parts of sodium carboxymethylcellulose and 37.5 parts of lactose, pulverize, sieve, mix, and then mix with duloxyl hydrochloride Mix 28 parts of Ting, add an appropriate amount of polyacrylic resin II medicinal ethanol solution as a binder, make a soft material, granulate through a 18-mesh sieve, and obtain wet granules. The wet granules are ventilated and dried at 50°C, sieved through a 18-mesh sieve, and an appropriate amount of magnesium stearate is added, and blended to make them uniform to obtain mixed dry granules. Sampling for determination of intermediate content. Calculate the weight of the tablet to be pressed according to the determination of the intermediate content, and press it into a tablet with a φ7 deep concave die, with a hardness of 8 to 10 kg, and then coat it with an enteric-coated material to make 40 mg of duloxetine hydrochloride (take duloxetine ...

Embodiment 2

[0029] Take 13.5 parts of hydroxypropylmethylcellulose K100M, 10.5 parts of glycine, 6.5 parts of sodium carboxymethylcellulose and 26.5 parts of compressible starch, grind, sieve, mix well, and then mix with 42 parts of duloxetine hydrochloride Mix evenly, add an appropriate amount of polyacrylic acid resin II medicinal ethanol solution as a binder, make a soft material, pass through a 18-mesh sieve and granulate to obtain wet granules. The wet granules are ventilated and dried at 50°C, sized through a 18-mesh sieve, added with magnesium stearate, and blended to make them uniform to obtain mixed dry granules. Sampling for determination of intermediate content. Calculate the weight of the tablet to be pressed according to the measurement result of the intermediate content, and press it into a tablet with a hardness of 8 to 10 kg, and then coat it with an enteric-coated material to make a slow tablet containing 60 mg of duloxetine hydrochloride (calculated as duloxetine) / tablet...

Embodiment 3

[0031] Take 16 parts of carbomer 940P, 10.5 parts of glycine, 8 parts of low-substituted hydroxypropyl cellulose, and 11.5 parts of lactose, pulverize, sieve, mix well, then mix well with 55 parts of duloxetine hydrochloride, add appropriate amount Ethyl cellulose solution is used as a binder to make soft materials, and granulated through a 18-mesh sieve to obtain wet granules. The wet granules are ventilated and dried at 50°C, sized through a 18-mesh sieve, added with magnesium stearate, and blended to make them uniform to obtain mixed dry granules. Sampling for determination of intermediate content. Calculate the weight of the tablet to be pressed according to the determination result of the intermediate content, and press it into a tablet with a hardness of 8 to 10 kg, and then coat it with an enteric-coated material to make a slow tablet containing duloxetine hydrochloride 120mg (calculated as duloxetine) / tablet. release tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Hardnessaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a duloxetine hydrochloride slow-released medicine. Said slow-released medicine is formed from duloxetine hydrochloride and acceptable auxiliary components in oral medicine, in which the duloxetine hydrochloride content is 15-65% of total weight of said medicine. The described auxiliary components at least include (by wt%) 1%-80% of high-molecular skeleton slow-release material, 0.1%-50% of releasing speed regulation component and 1.5%-10% of enteric solubility external coating material.

Description

technical field [0001] The invention relates to a medicine with enteric-coated slow-release function, more specifically a duloxetine hydrochloride slow-release medicine. Background technique [0002] Duloxetine hydrochloride is currently used for diseases such as depression and diabetic neuralgia, and for the treatment of female urinary incontinence. The method is to take it in divided doses according to the prescribed time every day. [0003] The chemical structure of duloxetine hydrochloride is as formula (I). [0004] [0005] Although the adverse reactions of this drug are relatively small among comparable drugs of the same kind, there are still obvious adverse reactions during the course of medication, especially nausea in the gastrointestinal tract is the most obvious, and the incidence rate can be as high as 23% to 28%. And it is also the main reason for patients to discontinue treatment, which limits the clinical dosage. Contents of the invention [0006] In ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/28A61K31/381A61P25/04A61P25/24
Inventor 钟声荣姜维平贾春荣
Owner CHONGQING SHENGHUAXI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com